Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
ACCESS Newswire (Thu, 19-Feb 7:30 AM ET)
Globe Newswire (Wed, 4-Feb 8:30 AM ET)
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Globe Newswire (Mon, 5-Jan 8:30 AM ET)
Market Chameleon (Thu, 18-Dec 4:37 AM ET)
Biodexa Announces Pricing of $10 Million Public Offering
Globe Newswire (Thu, 18-Dec 8:30 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Biodexa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BDRX.
As of March 6, 2026, BDRX stock price declined to $0.91 with 60,092 million shares trading.
BDRX has a beta of 0.54, meaning it tends to be less sensitive to market movements. BDRX has a correlation of 0.01 to the broad based SPY ETF.
BDRX has a market cap of $759,941.00. This is considered a Sub-Micro Cap stock.
BDRX has underperformed the market in the last year with a price return of -97.1% while the SPY ETF gained +18.7%. BDRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.0% and -21.9%, respectively, while the SPY returned -1.7% and -2.5%, respectively.
BDRX support price is $.87 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDRX shares will trade within this expected range on the day.
